Summary
Sexual-steroid-hormone-linked anticancer agents are a new group of cytotoxic drugs designed for a site-directed chemotherapy of tumors containing sexual steroid hormone receptors. The hormone (e.g. estradiol or testosterone) should act as a carrier that leads to a preferential receptor-mediated drug accumulation in hormone-receptor-positive tumors (such as mammary carcinomas and prostatic cancer). In several preclinical therapeutic studies of sexual-hormone-receptor-positive breast cancer, for instance, conjugates of 2-chloroethyl-carbamoyl-L-alanine linked to estradiol or dihydrotestosterone showed, in comparison to the unlinked single agent, a significantly higher antineoplastic activity and a clearly lower systemic toxicity. But there is still only limited knowledge about the pharmacokinetic properties and the mode of action of these new drugs. For this reason in the present article a more comprehensive pharmacokinetic model and the pattern of distribution of new sexual-steroid-hormone-linked anticancer agents have been described.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berger MR, Floride J, Schreiber J, Schmähl D, Eisenbrand G (1984) Evaluation of new estrogen-linked nitrosoureas. I. Short term anticancer efficacy in methylnitrosourea-induced rat mammary carcinoma. J Cancer Res Clin Oncol 108:118–153
Berger MR Henne T, Schmähl D (1985) Differential affinity of new estradiol-linked nitrosoureas in comparison with their respective single agents to tumour and bone marrow of methylnitrosourea-induced SC rats. Recent Adv Chemother 483–484
Berger MR, Floride J, Schmähl D, Schreiber J, Eisenbrand G (1986) Estrogen-linked 2-chloroethylnitrosoureas: anticancer efficacy in NMU-induced rat mammary carcinoma, uterine activity in mice and receptor interactions. Eur J Cancer Clin Oncol 22:1179–1191
Berger MR, Betsch B, Spiegelhalder B, Eisenbrand G, Schmähl D (1988) Pharmacokinetics and bioavailability ofN-(2-chloroethyl)-N-nitrosocarbamoyl-L-alanine in mammary tumor bearing Sprague Dawley rats. Eur J Cancer Clin Oncol 25:105
Betsch B (1988) Pharmakokinetische Studien mit Östradiolgekoppelten Nitrosoharnstoffderivaten an Ratten mit chemisch induziertem Mammacarcinom. Nachweis der erhöhten Affinität eines östradiolgekoppelten Zytostatikums zu Östrogenrezeptor positiven Geweben. M.D. Thesis, University of Heidelberg
Betsch B, Berger MR, Spiegelhalder B, Eisenbrand G, Schmähl D (1989a) New estradiol-linked nitrosoureas: can the pharmacokinetic properties help to explain the pharmacodynamic activities? Eur J Cancer Clin Oncol 25:105–111
Betsch B, Berger MR, Spiegelhalder B, Eisenbrand G, Schmähl D (1989b) Estradiol linked nitrosoureas: new anticancer agents with clearly modified pharmacokinetic properties. Eur J Clin Pharmacol 36 [Suppl.]: 308
Betsch B, Berger MR, Spiegelhalder B, Eisenbrand G, Schmähl D (1990a) New estradiol-linked nitrosoureas: are there perspectives for a site-directed chemotherapy of estradiol receptor positive breast cancer. Eur J Cancer Clin Oncol (in press)
Betsch B, Berger MR, Spiegelhalder B, Schmähl D, Eisenbrand G (1990b) Drug targeting in breast cancer: A site directed chemotherapy of estradiol-receptor positive mammary carcinomas with estradiol-linked nitrosoureas. Cancer Res Clin Oncol 116 (Suppl. Part 1): 425
Blossey HC (1985) Das Konzept der Site directed Chemotherapie Hormon-gekoppelter Zytostatika. In: Nagel GA, Hintze A (eds). Aktuelle Onkologie S 6–11
Corr R, Berger MR, Betsch B, Floride J, Brix HP, Schmähl D (1990) Modulation of cytosolic sexual steroid receptors in autochtonous methylnitrosourea induced rat mammary carcinomas following application of 2-chloroethylnitrosocarbamoyl-L-alanine linked to estradiol or dihydrotestosterone. Br J Cancer (in press)
Druckrey H, Raabe S (1952) Organspezifische Chemotherapie des Krebses (Prostatakarzinom) Klin Wochenschr 30:882–884
Eisenbrand G, Müller N, Schreiber J, Stahl W, Herzel WJ, Fiebig H (1986) Drug design. Nitrosoureas. In: Schmähl D, Kaldor IM (eds) Carcinogenicity of alkylating cytostatic drugs. IARC Sci Publ no 78, pp 281–293
Eisenbrand G, Berger MR, Brix HP, Fischer J, Mühlbauer K, Nowrowsian R, Przybilski M, Schneider MR, Stahl W, Tang W, Zelezny O, Zeller WJ (1989) Nitrosoureas — modes of action and perspectives in the use of hormone receptor affine carrier molecules. Acta Oncol 28:203–211
King RJB Mainwaring WIP (1974) Steroid cell interaction. University Park Press, Baltimore
Muggia FM, Lippmann M, Heuson JC (eds) (1978) Reports on the workshop on the use of steroid as carrier of cytotoxic in breast cancer. Cancer Treat, Rep 62:1239–1268
Petru E, Berger MR, Zeller WJ, Kaufmann M (1988) In vitro evaluation of estradiol-linked nitrosoureas in mammary carcinoma of mouse, rat and man. Eur J Cancer Clin Oncol 24:1027–1032
Ritschel WA (1976) Handbook of basic pharmacokinetics. Hamilton, Drug Intelligence Publications
Wagner JC (1976) Fundamentals of clinical pharmacokinetics. Hamilton, Drug Intelligence Publications
Zeller WJ, Schreiber J, Eisenbrand G (1985) Cytostatic activity of steroid-linked nitrosoureas on the MXT mammary carcinoma. Proc Am Assoc Cancer Res 26:250
Author information
Authors and Affiliations
Additional information
Dedicated to Professor Dr. D. Schmähl on the occasion of his 65th birthday
Rights and permissions
About this article
Cite this article
Betsch, B. The pharmacokinetic model and distribution pattern of new sexual-steroid-hormone-linked anticancer agents. J Cancer Res Clin Oncol 116, 467–469 (1990). https://doi.org/10.1007/BF01612995
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01612995